The estimated Net Worth of Merdad Parsey is at least $14.8 Million dollars as of 10 September 2024. Dr Parsey owns over 3,821 units of Gilead Sciences stock worth over $8,110,269 and over the last 5 years he sold GILD stock worth over $2,839,602. In addition, he makes $3,847,462 as Chief Medical Officer at Gilead Sciences.
Dr has made over 24 trades of the Gilead Sciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,821 units of GILD stock worth $309,272 on 10 September 2024.
The largest trade he's ever made was selling 12,984 units of Gilead Sciences stock on 1 March 2023 worth over $1,038,201. On average, Dr trades about 3,163 units every 45 days since 2019. As of 10 September 2024 he still owns at least 100,201 units of Gilead Sciences stock.
You can see the complete history of Dr Parsey stock trades at the bottom of the page.
Dr. Merdad V. Parsey M.D., Ph.D. is the Chief Medical Officer at Gilead Sciences.
As the Chief Medical Officer of Gilead Sciences, the total compensation of Dr D at Gilead Sciences is $3,847,462. There are 6 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.
Dr D is 58, he's been the Chief Medical Officer of Gilead Sciences since . There are 10 older and 14 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
Merdad's mailing address filed with the SEC is GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger, and John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: